Frontlight ResearchEarly access
WithdrawnPhase 2
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
Key facts
- Who runs it
- University of Michigan Rogel Cancer Center
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Oct 2019
- Ended
- Oct 2025
- Type of study
- Interventional
- Treatments tested
- Panobinostat
- Everolimus
- Record updated
- 19 August 2019
- Why it stopped
- low accrual
Who can take part
- Age
- 2 years to 30 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (28)Hide the full registry criteria
Who can take part
- All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents
- Patient must be greater than 2 years and less than 30 years
- BSA (body surface area) greater than 0.3 m2
- Functional status: Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients < 16 years of age (Karnofsky and Lansky is a scoring system used to quantify the general well being of cancer patients where 100% represents perfect health and 0% represents death). Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Adequate bone marrow function
- Adequate liver function
- Adequate renal and metabolic function
- Urine protein:creatinine (UPC) ratio of < 1; or a urinalysis that is negative for protein; or 24-hour urine protein level < 1000 mg/dL
- Patients must have Magnesium > 1.5 mg/dL and potassium > 3.5 mmol/L
- Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
- No increase in steroid dose within the past 7 days
- STRATUM A: histological confirmation of a newly diagnosed high-grade glioma or DIPG or STRATUM B: histological confirmation of a recurrent or progressive grade II-IV glioma (including DIPG) [histology can come from tissue at diagnosis or relapse]
- Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
- Myelosuppressive chemotherapy: Must not have received within 3 weeks (6 weeks if prior nitrosourea)
- Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long-acting (e.g. PEG-filgrastim)
- Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy with a biologic agent
- Radiation therapy: Strata A: ≥ 2 weeks and ≤ to 12 weeks must have elapsed from radiation. Strata B: ≥ 2 weeks must have elapsed from focal radiation
- Surgery: > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team
- Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed
- H3K27M mutation: Participants must have a mutation in H3.3 K27M or H3.1 K27M as identified by tumor (FFPE or fresh, diagnosis or relapse tissue, but relapse tissue preferred) sequencing, or by CLIA-certified immunohistochemistry staining positive for H3K27M, as defined by review by U of M neuro-pathology
Who cannot take part
- Other medications: Patients receiving other anti-neoplastic agents are excluded; patients on enzyme-inducing anticonvulsive agents are excluded; patients requiring strong CYP3A4 or PGP inducers or inhibitors are excluded; patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment
- Allogeneic stem cell transplant: Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded
- Previous hypersensitivity to rapamycin or rapamycin derivatives
- Patients with uncontrolled infection are excluded
- Baseline QTc of >450 msec on EKG OR electrolyte imbalance predisposing to QTc prolongation (baseline ≥ Grade 1 hypokalemia or hyperkalemia; and baseline ≥ Grade 2 Ca++, Mg++, phosphate abnormalities). Repletion/correction is allowed to achieve eligibility. Use of QTC prolonging medications will be monitored throughout the trial
- Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded. Abstinence is considered an effective form of birth control
- Inability to swallow oral pill (panobinostat does not have liquid formulation)
Where in United States
- University of Michigan Cancer CenterAnn Arbor, United States
About the trial
What the trial wants to find out
This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).
The group in the trial
- Panobinostat and EverolimusTreatment being tested
Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
Treatment: Panobinostat and Everolimus
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
- Record updated
- 19 August 2019